'Medical Machinery Huawei' | Mindray Medical listed on the 16th | plans to raise nearly 6 billion yuan
Medical Network October 16th, October 15th, Mindray Medical announced that it will be listed on the Growth Enterprise Market of Shenzhen Stock Exchange on October 16, 2018. It is understood that Mindray Medical will be listed in A-share in May 2017. Application, the second prospectus was issued in May 2018, and the meeting was successfully held on July 24. The issue price was 48.80 yuan/share, and the total amount of funds raised was 593.408 million yuan.
Figure 1: Composition of main business income (unit: 10,000 yuan)
Mindray Medical is known as 'Medical Machinery Huawei', mainly engaged in medical instruments R & D, manufacturing, marketing and services, products cover biological information and support, in vitro diagnostics and medical imaging three major areas, the main products are monitors, defibrillators, anesthesia machines, ultrasound diagnostic systems.
As the largest and largest global supplier of medical devices and solutions in China, it has 40 overseas subsidiaries in more than 30 countries in North America, Europe, Asia, etc. It has 17 subsidiaries and more than 40 branches in China. Formed a large global network of R&D, marketing and service. In 2017, revenue exceeded 10 billion, up to 11.174 billion yuan, and revenue from January to March 2013 was 3.23 billion yuan.
In the domestic market, Mindray Medical products cover nearly 110,000 medical institutions and more than 99% of the top three hospital , including Beijing Union Medical College Hospital, Shanghai Ruijin Hospital, etc. Famous doctor In the international market, it has won recognition from medical institutions in the United States, Britain, Germany, France and other countries. Mindray Medical said that the company's sales model is divided into direct sales and distribution, mainly in the United States, and in Europe. The country's industry characteristics adopt a model of direct sales and distribution coexistence. In China, Latin America and other developing countries and regions are mainly distribution.
Figure 2: R&D investment (unit: 10,000 yuan)
In recent years, Mindray Medical has continuously increased its R&D investment. In 2016, it exceeded 1 billion yuan. In 2017, it reached 1.132 billion yuan, accounting for 10.13% of revenue. As of the end of 2017, Mindray Medical had 1,764 R&D personnel, accounting for 21.2% of the company's total employees. %, distributed in Shenzhen, Nanjing, Beijing, the United States Silicon Valley and other eight R & D centers. In the future will allocate high-quality resources around the world, the integration of technology innovation capabilities of overseas R & D centers, customer demand and the efficiency of domestic R & D centers Engineering technology realization capability, establish a global research and development system.
Life information and support: Continuous innovation in monitoring new parameters, clinical decision-making and monitoring big data analysis, developing next-generation monitoring, anesthesia and ventilator products around 'intelligent', for intensive care, anesthesia, emergency, etc. The world's most competitive overall solution for clinical departments.
In vitro diagnosis: Focus on the automation line in the biochemical and immunological instruments, and the intelligence of the laboratory, and build a first-class coagulation detection system target, high-speed flux detection system, coagulation traceability system, new coagulation detection technology platform, etc. The field develops key technologies and productization, further expanding domestic technology leadership.
Medical Imaging: Strengthening further research on regional scanning imaging technology, continuous research and exploration in real-time 3D imaging, elastography, contrast imaging, etc., and carrying out intelligent data recognition based on big data in intelligent pattern recognition, intelligent auxiliary diagnosis, etc. Research, expanding the company's leading edge in global ultrasound imaging technology.
According to the prospectus, Mindray Medical expects to use the net proceeds of 5.75 billion yuan for the seven major investment projects. The fundraising investment project will expand on the basis of the existing main business, further breaking the existing capacity bottleneck. , improve production processes, enrich products and enhance product quality Further enhance the company's business scale and market position; expand the surgical product R&D and trial production center, upgrade the R&D innovation platform, enhance technical development examples, and provide a better innovation platform for the company's new product development; Upgrade the marketing service system, The construction of information systems will help deepen the market, broaden sales channels, and promote the company's continued health development of.
